[Fatal subfulminant hepatitis during treatment with alpidem (Ananxyl)].
Barki
J
J
Larrey
D
D
Pageaux
G
G
Lamblin
G
G
Gineston
J L
JL
Michel
H
H
D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D001247:Asthenia / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D007093:Imidazoles; D011725:Pyridines; C052036:alpidem
Hépatite subfulminante mortelle lors d'un traitement comportant de l'alpidem (Ananxyl).